{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T08:52:07Z","timestamp":1768985527537,"version":"3.49.0"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","contraceptionjournal.org","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Contraception"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.contraception.2024.110786","type":"journal-article","created":{"date-parts":[[2024,12,19]],"date-time":"2024-12-19T07:56:24Z","timestamp":1734594984000},"page":"110786","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Impact of progestin type on the risk of drug interactions between combined oral contraceptives and psychotropic drugs: A pooled analysis of real-world data"],"prefix":"10.1016","volume":"144","author":[{"given":"Tanja","family":"Boehnke","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Franke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anja","family":"Bauerfeind","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Klaas","family":"Heinemann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cornelia","family":"Kolberg-Liedtke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katja","family":"Koelkebeck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.contraception.2024.110786_bib1","unstructured":"United Nations Department of Economic and Social Affairs. Contraceptive use by method 2019: data booklet. 2019. https:\/\/www.un-ilibrary.org\/content\/books\/9789210046527\/\u00a0(cited November\u00a08, 2024)."},{"key":"10.1016\/j.contraception.2024.110786_bib2","first-page":"778","article-title":"Gender differences in psychotropic use across Europe: results from a large cross-sectional, population-based study","volume":"30","author":"Boyd","year":"2015","journal-title":"Eur\u00a0Psychiatry"},{"key":"10.1016\/j.contraception.2024.110786_bib3","first-page":"1","article-title":"FDA public meeting report on \"Drug Interactions With Hormonal Contraceptives: Public Health and Drug Development Implications\u201d","volume":"00","author":"Akbar","year":"2018","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.contraception.2024.110786_bib4","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/j.contraception.2016.07.011","article-title":"Drug interactions between hormonal contraceptives and psychotropic drugs: a systematic review","volume":"94","author":"Berry-Bibee","year":"2016","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2024.110786_bib5","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1080\/17425255.2022.2106214","article-title":"Drug-drug interactions between psychotropic medications and oral contraceptives","volume":"18","author":"Schoretsanitis","year":"2022","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1016\/j.contraception.2024.110786_bib6","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1111\/cts.12499","article-title":"Role of CYP3A in oral contraceptives clearance","volume":"11","author":"Zhang","year":"2018","journal-title":"Clin Transl Sci"},{"key":"10.1016\/j.contraception.2024.110786_bib7","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1002\/cpt.2690","article-title":"Development of a translational exposure-bracketing approach to streamline the development of hormonal contraceptive drug products","volume":"112","author":"Cicali","year":"2022","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.contraception.2024.110786_bib8","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1002\/cpt.1848","article-title":"The effects of weak and strong CYP3A induction by rifampicin on the pharmacokinetics of five progestins and ethinylestradiol compared to midazolam","volume":"108","author":"Wiesinger","year":"2020","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.contraception.2024.110786_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.contraception.2024.110375","article-title":"Systematic analysis of combined oral contraceptive prescription patterns in psychotropic drug users across twelve European countries","volume":"132","author":"Boehnke","year":"2024","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2024.110786_bib10","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/s40596-017-0806-1","article-title":"Residents perceive limited education on family planning and contraception for patients with severe and persistent mental illness","volume":"42","author":"Macaluso","year":"2018","journal-title":"Acad Psychiatry"},{"key":"10.1016\/j.contraception.2024.110786_bib11","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1080\/13625187.2021.1987410","article-title":"Prospective controlled cohort study on the safety of a monophasic oral contraceptive containing nomegestrol acetate (2.5mg) and 17\u03b2-oestradiol (1.5mg) (PRO-E2 study): risk of venous and arterial thromboembolism","volume":"26","author":"Reed","year":"2021","journal-title":"Eur J Contracept Reprod Health Care"},{"key":"10.1016\/j.contraception.2024.110786_bib12","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.contraception.2016.06.010","article-title":"Impact of estrogen type on cardiovascular safety of combined oral contraceptives","volume":"94","author":"Dinger","year":"2016","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2024.110786_bib13","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.contraception.2006.12.019","article-title":"The safety of a drospirenone-containing oral contraceptive: final results from the European Active Surveillance Study on oral contraceptives based on 142,475 women-years of observation","volume":"75","author":"Dinger","year":"2007","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2024.110786_bib14","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/1471-2288-9-77","article-title":"International active surveillance study of women taking oral contraceptives (INAS-OC study)","volume":"9","author":"Dinger","year":"2009","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.contraception.2024.110786_bib15","unstructured":"WHOCollaborating Centre for Drug Statistics Methodology. Guidelines for ATC classification and DDD assignment. https:\/\/www.whocc.no\/atc\/structure_and_principles\/\u00a0(cited November\u00a08,\u00a02024)."},{"key":"10.1016\/j.contraception.2024.110786_bib16","unstructured":"World Health Organization. ICD-10: International Statistical Classification of Diseases and Related Health Problems: tenth revision. 2004. https:\/\/iris.who.int\/handle\/10665\/42980\u00a0(cited November\u00a08,\u00a02024)."},{"key":"10.1016\/j.contraception.2024.110786_bib17","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1093\/oxfordjournals.aje.a114001","article-title":"Use of Poisson regression models in estimating incidence rates and ratios","volume":"121","author":"Frome","year":"1985","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.contraception.2024.110786_bib18","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1093\/biomet\/70.1.41","article-title":"The central role of the propensity score in observational studies for causal effects","volume":"70","author":"Rosenbaum","year":"1983","journal-title":"Biometrika"},{"key":"10.1016\/j.contraception.2024.110786_bib19","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1080\/00273171.2011.568786","article-title":"An introduction to propensity score methods for reducing the effects of confounding in observational studies","volume":"46","author":"Austin","year":"2011","journal-title":"Multivariate Behav Res"},{"key":"10.1016\/j.contraception.2024.110786_bib20","series-title":"Real world health care data analysis: causal methods and implementation using SAS","author":"Faries","year":"2020"},{"key":"10.1016\/j.contraception.2024.110786_bib21","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1093\/biomet\/asn055","article-title":"Dealing with limited overlap in estimation of average treatment effects","volume":"96","author":"Crump","year":"2009","journal-title":"Biometrika"},{"key":"10.1016\/j.contraception.2024.110786_bib22","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1080\/13697130500330309","article-title":"Added benefits of drospirenone for compliance","volume":"8","author":"Foidart","year":"2005","journal-title":"Climacteric"},{"key":"10.1016\/j.contraception.2024.110786_bib23","doi-asserted-by":"crossref","first-page":"325","DOI":"10.2165\/11535450-000000000-00000","article-title":"Effects of oral contraceptives containing ethinylestradiol with either drospirenone or levonorgestrel on various parameters associated with well-being in healthy women: a randomized, single-blind, parallel-group, multicentre study","volume":"30","author":"Kelly","year":"2010","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.contraception.2024.110786_bib24","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1097\/EDE.0000000000001302","article-title":"A pharmacoepidemiologic approach to evaluate real-world effectiveness of hormonal contraceptives in the presence of drug-drug interactions","volume":"32","author":"Sarayani","year":"2021","journal-title":"Epidemiology"},{"key":"10.1016\/j.contraception.2024.110786_bib25","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.seizure.2019.11.011","article-title":"Bidirectional interaction between oral contraception and lamotrigine in women with epilepsy - role of progestins","volume":"74","author":"Rauchenzauner","year":"2020","journal-title":"Seizure"},{"key":"10.1016\/j.contraception.2024.110786_bib26","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1093\/aje\/kwm165","article-title":"The impact of residual and unmeasured confounding in epidemiologic studies: a simulation study","volume":"166","author":"Fewell","year":"2007","journal-title":"Am J Epidemiol"}],"container-title":["Contraception"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0010782424005006?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0010782424005006?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,8]],"date-time":"2025-03-08T19:44:06Z","timestamp":1741463046000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0010782424005006"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":26,"alternative-id":["S0010782424005006"],"URL":"https:\/\/doi.org\/10.1016\/j.contraception.2024.110786","relation":{},"ISSN":["0010-7824"],"issn-type":[{"value":"0010-7824","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of progestin type on the risk of drug interactions between combined oral contraceptives and psychotropic drugs: A pooled analysis of real-world data","name":"articletitle","label":"Article Title"},{"value":"Contraception","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.contraception.2024.110786","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"110786"}}